Suchergebnisse - "Rimassa, Lorenza"

PubPharm (29)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

Plain language summary of the HIMALAYA study : tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

enthalten in: Future oncology (London, England) | 2023

von Abou-Alfa, G. | Lau, G. | Kudo, M. | +27

3

Combination immunotherapy for hepatocellular carcinoma

enthalten in: Journal of hepatology | 2023

von Rimassa, L. | Finn, R. | Sangro, B.

4

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice : Results of the AB-real study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Fulgenzi, C. | Cheon, J. | D'Alessio, A. | +34

5

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

6

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

enthalten in: Journal of hepatology | 2022

von Scheiner, B. | Pomej, K. | Kirstein, M. | +38

CommentIn: J Hepatol. 2022 Apr;76(4):987-988. - PMID 34780876

7

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma : matching-adjusted indirect comparison analysis

enthalten in: Journal of cancer research and clinical oncology | 2021

von Casadei-Gardini, A. | Rimassa, L. | Rimini, M. | +15

8

Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

enthalten in: Clinical drug investigation | 2021

von Ryoo, B. | Palmer, D. | Park, S. | +6

ErratumIn: Clin Drug Investig. 2022 Mar;42(3):283. - PMID 35220556

9

Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma : An inverse probability of treatment weighting analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2021

von Casadei-Gardini, A. | Scartozzi, M. | Tada, T. | +24

CommentIn: Liver Int. 2021 Jun;41(6):1432. - PMID 33872444

10

Impact of age on sorafenib outcomes in hepatocellular carcinoma : an international cohort study

enthalten in: British journal of cancer | 2021

von Hajiev, S. | Allara, E. | Motedayеn Aval, L. | +15

ErratumIn: Br J Cancer. 2021 Feb 3;:. - PMID 33531694